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Abstract 
As the work environment changes, the demands on working people change. Particularly cognitive 
abilities are becoming more and more important for work performance and successful competition in a 
global environment. However, work-related stress, performance over long hours, lack of sleep, shift 
work and jet lag affect cognitive functions. Therefore, an increasing number of healthy people are 
reported to use cognitive enhancing drugs as well as other interventions such as non-invasive brain 
stimulation to maintain or improve their work performance. This review summarizes research on 
pharmacological and technical methods as well as cognitive training studies, including game apps for 
the brain, in healthy people. In neuropsychiatric disorders, impairments in cognitive functions can 
drastically reduce the chance of returning to work. This review also summarizes research on 
pharmacological and cognitive training studies in neuropsychiatric disorders. 
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Introduction 
When the financial crisis in Greece was at its climax in July 2015, European politicians such as 
Angela Merkel, David Cameron and the Greek finance minister Yanis Varoufakis were in close 
contact, and even US president Barack Obama was involved due to potential global economic 
consequences of the crisis. They were meeting in small groups, holding phone conferences, debating 
and negotiating over days into the early morning hours1. This might have been a rather exceptional 
situation, but similarly critical and hectic constellations occur again and again in the life of politicians. 
It is a highly demanding situation, because the individual politician has to stay sharp, focused, 
controlled, and be able to make decisions with potentially far-reaching consequences. And he or she 
often has to keep up this high-functioning state over days and potentially weeks. One historical case 
where a politician has admitted using pharmacological ‘helpers’ such as barbiturates and 
amphetamines to be able to fall asleep and to be fit the next day again is the former British prime 
minister Anthony Eden 2, which has been shown to have affected his decision making 2.  
Although life for  most people is not as tightly clocked and does not involve decisions about the fate of 
states or war, the 9 to 5 Monday to Friday work rhythm assumed to be the norm is changing: In the 
last 150 years, the employment structure and thus the work environment for the majority of workers 
has changed dramatically: Until about 1911, about equal proportions of workers in the UK worked in 
manufacturing and services (40% each), whereas in 2011, more than 80% of workers worked in the 
service industry with less than 10% in manufacturing and agriculture/fishing3. This means that the 
majority of workers now rather use their brains and their minds instead of their muscles, and now 
maintaining and improving brain function has come into the focus of education and other 
Governmental departments 4. This trend is even increased by the digital technology development 
which is visibly eroding employment in manufacturing and retail as well as having an impact on 
highly skilled services in multiple areas 5.  
A recent report by the International Labour Organization on the changing nature of jobs 5 describes the 
changes in work environment over the last 10 years. It identified increasing rates of part-time 
employment, accompanied by a decrease in full-time employment, and a considerable proportion of 
workers without permanent contract (about 25% in high-income countries, tendency increasing). In the 
advanced economies and EU category, these workers in non-permanent contracts are most affected by 
poverty (between 16 and 40%). Furthermore, the proportion of unemployed workers receiving 
unemployment benefits in high income economies has decreased from 44% in 2009 to 35% in 2014. 
This reduction in benefits and insurances for the case of unemployment in turn increases the pressure 
on those in work to perform and to satisfy work demands. In addition, the increasing trend towards 
jobs involved in the global supply chain (2014: >30% in the EU, about 10% in the US5), e-commerce 
and extended availability of online and offline services in a (nearly) 24/7 style will increase the 
demand for ‘white collar’ workers around the clock6. About 22% of workers globally are reported to 
work more than 48 hours per week (US: 18.1%7). Regarding shift work the most recent US data are 
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from 2004, reporting over 15 million full-time wage and salary workers (14.8%) who are given shift 
schedules (fallen slightly since 1991 (18%), but clear difference to 1985 (16%)8). In Germany, the 
percentage increased during the late 1990s, and is now at a plateau of about 17% (2013)9, identical to 
the percentage in the UK in 201410. Shift work has particularly been associated with negative acute 
and long-term health effects such as subjective fatigue, reduced quality and quantity of sleep, reduced 
quality of life11, increased anxiety, depression, adverse cardiovascular effects12, increased risk for 
gastrointestinal disorders13, metabolic syndrome14, possibly increased cancer risk15, 16 as well as higher 
incidence of accidents and errors during work17 and a higher risk of commuting accidents (review6).  
The amount of sick leave days due to mental disorders (notwithstanding the phenomenon of 
presenteeism) has increased markedly in the last decades: it increased, for instance, by 209% from 
1997 to 2014 in the population covered by one of the main German health insurance companies, while 
the amount of sick leave days due to all disorders increased only by 21% in the same time18. Mental 
disorders are now the second most frequent reason for sick days (after musculo-skeletal problems)18. 
The causality between these two phenomena, the change in workplace conditions and the change in 
the prevalence and severity of mental disorder, is not clear. However, independent of causality, the 
direct economic effects of mental problems are becoming an increasing factor for companies and also 
for national economies. 
These changes in work environment and the ever increasing demands on cognition associated with 
these contribute to the tendency to use strategies to improve work performance. There are several 
methods to enhance cognitive functions which can be differentiated into pharmacological (‘smart 
drugs’, ‘neuroenhancers’) and non-pharmacological strategies, including physical exercise, diet, sleep 
meditation as well as technical devices (transcranial stimulation) and computer games and apps aimed 
at boosting brain function19-21. We will focus on pharmacological enhancers using the Neuroscience 
based Nomenclature system22), but not generally consumed widely available substances such as 
caffeine, in the following section, and discuss the current state of other methods in the last section. 
 
But not only politicians, bankers or academics23, 24 are taking pharmacological ‘helpers’. But this 
option of using pharmacological ‘helpers’ or cognitive enhancers to face the ever increasing stress and 
demands of the work environment appeals also to a wide range of people: A report25 in 2015, issued 
by a big German health insurance company, contacted 10213 insured people (age range 20-50 years 
old) of which 5017 responded (49.1%). Of the respondents, 6.7% reported the life-time use of 
pharmacological neuroenhancement (increase from 4.7% in the previous report issued in 2009), 3.3% 
with the aim to improve work-related performance, 4.7% with the aim to improve mood and anxiety. 
However, the authors report that the rate of 6.7% might underestimate the true value due to response 
bias. The estimated 1-year prevalence was 5.8% with 63% of users reporting regular, more than once a 
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month intake. This study focused on the intention of using prescription drugs rather than the specific 
pharmacological agents. The users reported medications aimed at reducing anxiety/nervousness, 
antidepressants, stimulants, beta-blocker, and medications aimed at improving memory 
(antidementiva). Work environments with high prevalence were characterized by high pressure 
(serious consequences due to small mistakes), work situation with low employments security, a 
requirement not to show emotions and working at the limit of capabilities. In summary, this report 
showed an increasing frequency of the use of pharmacological substances with the aim of improving 
work-related performance, which amounts to up to 5 million people in Germany (population: 82.6 
million). Despite repeated alarming headlines in newspapers26-33, data on the use of cognitive 
enhancers in work environments from other countries are rare19. In student populations, several studies 
found prevalences between 2 and 25% in various countries, with most studies ranging around 10-
15%19, 34, 35. Furthermore, most research on the enhancing effects of pharmacological and other 
enhancing mechanisms such as transcranial electrical or magnetic stimulation (eg. tDCS, tMS) has 
until now only investigated effects of single (maximum few) intakes on well-defined cognitive tests36.  
From an ethical and policy perspective, however, the use of neuroenhancing interventions should be 
carefully considered. On the one hand, impaired cognition due to stress, shift work, or other effects 
can reduce overall GDP of a nation, be it directly by diminishing productivity or indirectly due to the 
effects of accidents or long-term effects of stress and work-related disorders such as musculoskeletal 
and mental disorders (e.g. 37). In addition, chronic stress can also negatively affect cognitive function, 
particularly forms of memory 38 as well as brain volume39, 40.  
The above mentioned German survey25 suggests that particularly people who are either worried about 
their job, working at the limit of their capabilities or in fields where small mistakes can have serious 
consequences, seem to be particularly prone to using cognitive enhancers25, and the users reported the 
following motives for use: for specific situations (such as exams, giving a presentation, important 
negotiations, etc., reported by 41%), because work is easier (reported by 35%), I can reach my goals 
easier (32%), more energy and better mood for other interests (27%), competitive edge at work (12%), 
would not be able to do the work otherwise (25%), need less sleep (9%). This is in parallel to studies 
investigating the motivation of students who consume cognitive enhancers, reporting mainly 
increasing performance and ‘keeping up’ (concentration, vigilance, memory, cognitive potential), 
staying awake for longer periods and a pressure to succeed as well as a way to maintain an active 
social life41-43. In addition, factors such as overcoming jetlag and improving focus and increasing 
motivation for tasks over longer times are known reasons for taking drugs such as modafinil21, 23, 44, 45. 
One important point when talking about cognitive enhancers is the differentiation between its use as 
treatment which is usually understood as aimed at improving a measurable deficit, related to a 
neuropsychiatric disorder compared to the use of cognitive enhancers with the aim of improving a 
Page 5 of 41
http://www.nyas.org/forthcoming
Annals of the New York Academy of Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
unedited manuscript
6 
normal cognition in a healthy person above their typical function or to maintain cognition for longer 
times or despite sleep deprivation or jet-lag.  
In patients suffering from neuropsychiatric disorders, deficits can be easily measured, and no-one 
would dispute the use of drugs or other interventions to improve clinical deficits which might enable 
patients to lead independent lives, return to work and have a better quality of life and wellbeing. 
However, when looking at cognitive enhancement in people without a clear diagnosis of a mental 
disorder, it is difficult to define the terms “normal cognitive function” and “deficit” (e.g. 21): What 
defines “normal cognitive function”? It might seem rather easy to determine if someone has clear 
cognitive deficits, for instance, after a stroke or as is the case in chronic schizophrenia. However, it is 
more difficult in people without a clear medical disorder, but subjective deficits or in people who wish 
to improve their cognitive performance above their “normal” level or want to maintain their level 
despite being sleep-deprived or jet-lagged or maybe noticing an aging-related decline. Therefore, it is 
difficult whether to describe the use of a cognitive enhancing drug in these situations as restoration or 
as enhancement21.  
In addition to these definitional questions, there are also questions as to which cognitive enhancing 
methods are really effective and in which populations (healthy/patients) and for which cognitive 
domains. It is also important to know whether effects measured in an experimental laboratory setting 
can be translated into everyday performance and functioning. Besides ‘smart drugs’ a number of other 
methods aim at improving cognitive function such as cognitive training, possibly using novel technical 
methods such as games and smartphone applications, electrical or electromagnetic methods such as 
transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (TDCS) which aim 
at directly modulating brain areas or networks to improve cognitive performance.  
The aim of this review is to summarize the state of current knowledge on enhancing and restoring 
cognition in healthy participants and in patients suffering from neuropsychiatric disorders with a 
particular emphasis on novel findings published in 2014 and in 2015.  
Studies on pharmacological cognitive enhancers in healthy volunteers 
In general, pharmacological cognitive enhancers used by healthy people can be grouped into several 
categories: stimulant-types (amphetamines, aimed at improving vigilance, attention, focus, speed of 
processing), modafinil (which has some similarities to amphetamines, but also differential effects)46, 
drugs used to treat dementia (acting on acetylcholine and/or glutamate, aimed at improving memory) 
47, and due to the link between motivation/mood and cognitive performance, people are also using 
drugs that improve sleep, reduce anxiety (e.g. benzodiazepines) and improve mood (SSRIs)25. 
In the years 2014 and 2015 (until October 2015), there were several new studies on cognitive 
enhancers and particularly a couple of important reviews and meta-analyses aimed at finding evidence 
in the vast number of small scale studies (summary in table 1). Battleday and Brem48 performed a 
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7 
systematic review on 24 studies using modafinil (mixed pharmacology, acting primarily as a blocker 
of dopamine and noradrenaline reuptake transporters49 and various effects on other neurotransmitter 
receptors46, 50, 51) on cognitive tasks in healthy not sleep deprived participants, showing no consistent 
effect on tests of attention, but generally positive effects on inhibitory control and working memory. 
More clearly beneficial effects of modafinil were found in tests of ‘higher’ executive function such as 
planning (e.g. 45, 52), decision making and fluid intelligence (e.g. 53). In tests of delayed memory, the 
authors report about as many positive studies as studies with no or with negative effect. However, in 
more complex paradigms, which are less standardized, but might be more ecologically valid, a number 
of studies found improved performances. Some studies have demonstrated baseline-dependent effects 
with low performing subjects showing improvements in performance following stimulant drugs, but 
those subjects with an already high baseline performance showing no change or even impairment 
following stimulant drugs. However, in comparison to studies on typical stimulants (particularly 
methylphenidate (MPH) and amphetamines, both acting on dopamine, noradrenaline and serotonine 
reuptake transporters54-56), there seem to be no substantial baseline-dependent effects with modafinil. 
Sleep-deprived healthy subjects show cognitive enhancement with modafinil in tests of executive 
function (working memory, planning, decision making, flexibility)57 as well as sustained attention58. 
For prescription stimulants, comprising amphetamines and MPH, the meta-analysis by Ilieva et al.59 
(48 studies) confirmed small but significant effects on inhibitory control and short-term memory, a 
medium effect on delayed memory, and a borderline significant small effect on working memory in 
healthy adults. Similarly, the review by Linssen et al.60 on single dose studies of MPH in healthy 
volunteers reported clear effects on working memory (particularly with a medium dose (10-20 mg)) 
and processing speed, weaker effects on learning and memory, attention, and an even weaker effect on 
decision making and problem solving. Visual learning and memory were not affected across studies, 
and studies in older adults showed weaker to no beneficial effects compared to younger adults (with 
the limitation of fewer studies). One study investigated the effect of MPH on the interaction between 
salience and attentional control, showing that MPH actually increased the distractor cost, i.e. the effect 
of a salient distractor on attention is increased61. The main motives for healthy people to consume 
pharmacological cognitive enhancers are various (see above)25, 41. One study reported that people with 
subclinical traits related to ADHD, impulsivity and novelty seeking were more prone to using 
cognitive enhancers62. However, it is possible that people self-medicate or at least try to self-medicate 
for undiagnosed ADHD traits or subjective cognitive deficits63 as well as for motivational problems45, 
64 and diminished inhibitory control resulting in increased impulsivity65. Another study reported 
similar subjective attention impairments/ADHD symptoms, but also increased omission errors in an 
attention test in users of (unprescribed) stimulants66. However, there is evidence from a number of 
studies that poor baseline performance predicts cognitive improvement in response to stimulant intake 
(e.g. 67-70), which might correspond to the dopamine state in the thalamocorticostriatal network71, 72. 
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8 
One recent review summarized over 50 studies on other drugs that potentially could enhance cognition 
such as those exerting actions through other pharmacological mechanisms, including through other 
catecholaminergic mechanisms, action on glutamate, acetylcholine, and histamine47. Of these, most 
were negative (no enhancing effects) or conflicting studies, except for some positive effects by 
tolcapone (inhibits dopamine degradation in the brain) and Levodopa on memory. Further 
pharmacological interventions acting on melatonine or anti-inflammatory drugs showed positive 
cognitive effects, but only in single studies. 
There are other interventions at the border between pharmacology and nutrition, one being poly-
unsaturated fatty acids (PUFAs) which are thought to enhance brain function. One recent meta-
analysis of studies in healthy volunteers and in patients suffering from attention-deficit hyperactivity 
disorder (ADHD) showed a potential beneficial effect on working memory in ADHD, but no 
significant consistent effects across both healthy and ADHD participants, except for a small effect in 
PUFA deficient participants in the domains of working memory and short term memory. The authors 
concluded that more studies are needed. Another supplement, resveratrol, which is thought to have 
neuroprotective effects, showed no benefits for cognitive performance in healthy volunteers73. 
 
Non-pharmacological interventions to enhance cognitive performance in 
healthy subjects 
First, there are a number of well established methods which can help maintaining optimal cognitive 
performance (summary see table 2). The UK Government’s Foresight Report on Mental Capital And 
Wellbeing74 has recognized and summarized a number of well-founded strategies for the individual 
and for policy makers to maintain and optimize wellbeing and performance in general and in 
workplace environments, based on research that wellbeing is related to better cognitive function75. The 
Foresight report formulated five basic ways to improve wellbeing based on scientific evidence:  
- Physical exercise (be active),  
- Keep learning – referring to the concept of lifelong learning, ongoing challenges and the 
improved confidence when conquering the challenge, 
- Connect – valuing and fostering social contacts, 
- Mindfulness (take notice) – being open to new experiences, and also being aware of your 
environment and your own wellbeing, 
- Give – the rewarding effects of a positive attitude towards others and the positive effect of 
helping someone. 
For all these factors, there are multiple studies showing beneficial effects at the neurobiological level 
(general reviews76, 77; studies on aerobic exercise resulting in increased brain derived neurotrophic 
factor (BDNF)78, 79, increased neurogenesis in mice80 and improved cognition and increased 
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9 
hippocampus size in humans81 (however, also 82); extensive literature on enrichment enhancing 
cognition in rodents, reviews76, 83). Furthermore, interventions in early childhood can help improving 
resilience against future adverse influences and also mitigate the effects of early low socioeconomic 
status on cognitive and emotional development84-86 (examples of interventions: 87, 88, review of family-
based interventions: see 89).  
In addition, it is well known which factors affect cognition and wellbeing negatively, such as lack of 
(quality) sleep, poor nutrition, chronic stress effects, inadequate levels of demand (either excessive or 
not sufficient, i.e. boredom). Furthermore, a number of disorders and disturbances in somatic function 
can affect cognition negatively, for instance sensory impairments (vision, hearing), metabolic and 
endocrine imbalances, neurotoxic substances such as alcohol and other solvents, traumatic brain 
injuries, including even mild brain injury. Avoiding or reducing the effect of these negative influences 
represents therefore a very basic mechanism to preserve cognitive performance. Furthermore, 
interventions such as mindfulness, meditation and relaxation training could prevent the building up of 
stress and thus prevent the impairment of cognition by stress in addition to possibly direct 
improvements in domains such as attention, executive function and memory (e.g. 90, review in 91).  
More specific cognitive training approaches have used various methods ranging from paper and pencil 
based interventions, book reading (e.g. 92) to computerized training to training programmes integrated 
into video games (e.g. 93, 94). The target of this training varies from circumscribed functional domains 
such as attention95 to broad multi-domain cognition96. The video-game industry, worth more than £3.9 
billion in the UK (2014)97, and more than $6.2 billion in the USA (2012)98, has developed great 
strategies to grab the player’s attention, create and maintain motivation to play over long time periods 
and even to tap into brain networks associated with reward and addiction99-101. Certain video games, 
while not having the explicit aim to improve cognition, seem to have some similar broad effects on 
cognitive function as specific, targeted “brain training” games102, in terms of improving reaction time, 
speed of response and in some cases attention. In addition, both brain training games and video games 
are now more and more accessible via the internet, providing a training opportunity for large parts of 
the population103. However, a larger meta-analysis found that the effects of computerized cognitive 
training in older adults were significant, but relatively small104. From a conceptual and scientific 
perspective and also to target more specific cognitive domains, research has in the last decade aimed at 
integrating directed cognitive training into video games, using the strategies of “professional” 
commercial video games and thereby having the potential to overcome the motivational problems 
evident with classical cognitive trainings (e.g. non-completion rates of > 50% in study settings in a 
rehabilitation program105). Overall, however, it is not clear yet how factors such as motivation, fun and 
adaptivity of the game best come together to result in maximal improvement of the trained functions, 
and, even more important, in a transfer of the training effect into other, related, but not directly trained 
functions, and in the best case into everyday functioning106, 107. Some models propose that one 
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10 
important aspect of successful training in video games is that the players “learn to learn”108, 109 or the 
improvement of multitasking and general cognitive control110 which might explain the different 
degrees of transfer or generalization found with different games.  
In the field of working memory and executive function training, a small but significant improvement 
of fluid intelligence has been shown in a meta-analysis111 as well as into academic performance in 
children with low baseline performance and, although to a lesser degree, in children with average 
baseline performance112. However, the relevance of baseline performance to the possible gain with 
training is not totally clear. For example, children with lower baseline may benefit more from training, 
whereas in older adults those with higher baseline education seem to perform better with training112. In 
older adults, one specific everyday domain has received some attention: the development of specific 
training programs for improving car driving performance and safety with rather consistent successful 
results113-115. 
One potentially important but yet underresearched question, however, is the optimal “dosage” of all 
these interventions: If a person tries to improve cognition by doing a lot of cognitive training, this 
might, if excessive and highly time consuming, may be associated with a significantly increased 
sedentary time, reduced physical exercise and reduced social interaction, which all can then counteract 
the beneficial effect of the cognitive training. There are few studies looking at combinations of 
different interventions (mostly combinations of exercise and cognitive training, in some studies 
additional nutritional interventions), and most of these are done in cohorts of older adults. There is 
some evidence that the combination of cognitive and physical training is more efficacious than 
cognitive training alone (e.g. 116). In most of these studies, interventions were done in a group setting, 
such that the social interaction (if within the group or with members of the teams) was enhanced with 
any intervention (e.g. 117) and can therefore not be separated as factor. In younger adults, however, 
there is nearly no research on this question. Future studies should focus on, the optimal balance of 
activities and interventions on cognition, which has until now been neglected. 
In the last decades, methods of directly modulating brain activity have been developed with the 
intention to enhance cognitive performance directly or to increase the efficacy of cognitive training. 
One such group of interventions are non-invasive brain stimulation methods, particularly transcranial 
magnetic and electrical stimulation. Transcranial Magnetic Stimulation (TMS) has direct effects on the 
activity of circumscribed (mostly cortical) neuronal populations resulting in either a direct activation 
(depolarization, excitation) or an inhibition (‘virtual lesion’)118. This effect interacts at least partially 
with the individual’s cognitive and physiological state119. In cognitive research, TMS has been shown 
to have quite robust effects in a variety of domains (depending on the targeted brain region) such as 
motor learning, sensory discrimination, attention, inhibition, working memory120, 121. Nevertheless, due 
to the more complex application and the higher costs of TMS machines, this method is not expected to 
hit applications for use outside research or clinical environments. Transcranial electrical stimulation 
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11 
methods, particularly transcranial direct current stimulation (tDCS), aim at changing the excitability of 
larger brain areas by modulating the neuronal response threshold, but not inducing action potentials. 
At the functional level, this intervention is thought to facilitate or inhibit brain processes and to 
modulate brain plasticity118. Transcranial alternating current stimulation (tACS) aims at influencing 
frequency-specific brain activations whereas transcranial random noise stimulation (tRNS) is thought 
to apply a repeated subthreshold stimulation and therefore boosting the overall sensitivity of neuronal 
networks118. Particularly tDCS has gained media attention again and again with headlines such as 
‘Headset zaps video gamers’ brains for better reflexes’122, ‘Keep Calm and Carry on’123 or ‘Zap Your 
Brain to Health with an Electrode Cap’124, but also warnings such as ‘Warning over electrical brain 
stimulation’125 and an impairing effect of a commercially available tDCS headset on working 
memory126. However, despite some positive reports and even higher hopes in the beneficial effects of 
tDCS (e.g. 36, 127), a recent meta-analysis came to the conclusion that it has, if at all, only a weak effect 
on cognition in healthy subjects128 and, for instance, in stroke patients129, although the former meta-
analysis has been criticised for being overly conservative130, 131. This finding, however, might in 
addition be due to heterogeneity associated with a lack of knowledge about, for instance, differential 
effects of electrode placement and other stimulation parameters119. Therefore, research is urgently 
needed to investigate mechanisms, optimal parameters and objective effects as well as effects of 
repeated and long-term use, because the unregulated application of DIY neurostimulation devices in 
this field is increasing132. 
Using a related and non-invasive approach, methods such as EEG and fMRI based neurofeedback 
have been shown to enhance the control over or the function of specific brain circuits133-136 and 
enhance cognitive-perceptual processes137, 138. However, while the relation between signal (i.e. activity 
of a brain region or connectivity between brain regions) and function is rather well understood in the 
case of fMRI neurofeedback, this direct correlation is much less understood in EEG neurofeedback139, 
140.  
Nevertheless, one field that requires more research is the optimal design of training programs (dosage, 
duration, etc.) and how to ensure the transfer of a practiced skill, if using neurofeedback or other 
training methods, onto other, more or less related cognitive tasks and, more importantly, into everyday 
life.  
 
Studies on pharmacological cognitive enhancers in neuropsychiatric 
disorders (table 1) 
Neuropsychiatric disorders are highly prevalent in the general population (18.5% 1-year prevalence in 
the adult US population)141. These disorders and the cognitive disturbances associated with them 
represent major problems for the ability to work, be productive and the society as a whole18, 142, 143. 
Neuropsychiatric disorders are characterized by cognitive disturbances including biased attention, 
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aberrant learning, dysregulated motivation and emotion and impaired top-down control of our multiple 
processes typically attributed to the prefrontal cortex20, 21, 144. Many neuropsychiatric disorders start 
early in life, some with a prodromal stage, they affect young people disproportionally (75% of mental 
illnesses begin before the age of 24 years)145 and they have serious consequences for the functionality 
and wellbeing of the individual and the economic development of the society4, 146. In some of the 
neuropsychiatric disorders, cognitive deficits are obvious and have long been targets of treatment, 
most clearly in dementias and also in ADHD. In others such as depression and schizophrenia, most 
treatments available until now target the more acute symptoms such as mood or psychosis. However, 
the cognitive symptoms often persist after remission of the acute symptoms147-153 and are associated 
with serious effects on social and interpersonal functioning, such as fewer than 20% of patients with 
schizophrenia returning to work after a first psychotic episode154. It is now clear that cognitive 
impairment in schizophrenia and depression is an unmet need and a target for treatment (155. One 
problem in studies on cognitive enhancing interventions in neuropsychiatric disorders is that a number 
of studies used clinical scales summarizing global functions associated with cognitive deficits or 
cognition in everyday situations (e.g. CGI, MMSE in dementia, PANSS in schizophrenia) rather than 
using specific cognitive tests. 
In Alzheimer’s disease (AD) and other dementias (or neurocognitive disorders as they are now called 
in the DSM-5156), cognitive symptoms are the main aspects157. Therefore, research has already since 
the late 1970s investigated drugs to enhance or even restore cognitive function, particularly memory, 
using cholinergic mechanisms (e.g. 158, 159) resulting in tacrine as the first acetylcholinesterase inhibitor 
(AChEI, blocking the degradation of synaptic acetylcholine) approved for use in AD160. Since then 
these drugs have been the most successful treatments in AD, even if they are primarily aimed at 
symptomatic treatment, rather than at the underlying pathology of the disorder. In parallel, research 
has been trying to develop causal treatments, which would halt the underlying disease processes are, 
however, still in clinical trials. In the last year, one meta-analysis confirmed the clear positive effects 
of the AChEIs donepezil, galantamine and rivastigmine as well as the NMDA-receptor antagonist 
memantine (acting on the glutamate system) on cognition and general functional outcome in AD161. 
However, using less sensitive subjective measures such as clinical global impression, only donepezil 
was clearly superior to placebo, with rivastigmine improving only clinical impression. Three recent 
studies162-164 have shown that treatment with cholinesterase inhibitors not only improves functional 
outcome, but also is cost-effective. Therefore early detection and early effective treatment with 
AChEIs is important. Early detection will become even more important when neuroprotective drugs 
and drugs targeting the disease process causally will become available. From a health-economic 
perspective, a recent study showed that treatment with cognitive enhancing drugs (ACHEI and 
memantine) in AD clearly reduced total costs (direct and indirect) compared to no treatment165. In one 
study, the beneficial effect of donepezil on cognition and overall outcome was not correlated with 
hippocampal volume166. In contrast, in untreated patients cognitive deficits and hippocampal atrophy 
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were correlated, whereas this was not the case in donepezil treated patients166. One study showed also 
improvement in gait performance due to donepezil treatment in AD167. In 2014 and 2015, there were 
furthermore a handful of studies using galantamine confirming its beneficial effect on some cognitive 
domains for a duration of 6-12 month, and thereafter the drug slowed the progression of 
deterioration168-170. In terms of novel treatment approaches published in 2014 and 2015, particularly 
histamine H3 receptor antagonistic approaches have been tested171-173, as well as rapid acting 
insulin174. Further studies investigated the effects of benzoate (aiming at enhancing NMDA receptor 
function) showing an improved cognitive performance and global clinical impression in a randomized 
placebo-controlled study over 24 weeks in 60 patients175.  
In Dementia with Lewy Bodies, a neurodegenerative disorder with a different pathophysiology and 
different symptom profile compared to AD, a recent meta-analysis176 found a beneficial effect of the 
ACHEIs donepezil and rivastigmine for cognitive functioning as well as for other symptoms such as 
visual hallucinations, but only limited evidence for other drugs targeting cognition such as 
galantamine and memantine.  
Next to the dementias, schizophrenia is the neuropsychiatric disorder where cognitive deficits have 
long been described177, 178 and are considered to be an important target for treatment179 due to their 
relationship to functionality. However as yet, the relationship between antipsychotic treatment and 
cognition in schizophrenia is mixed180, with some antipsychotics coming out as being superior in 
certain domains but apparently impairing function in another domain. For example, verbal fluency was 
shown to be improved by clozapine, but in contrast, verbal memory was impaired by clozapine 
(atypical antipsychotic drug primarily acting on serotonine receptors, 5HT2A181), in comparison to 
other antipsychotics180, 182-184. Recently, research has aimed at developing drugs that reduce so-called 
positive symptoms (i.e. hallucinations, psychosis) and also improve cognition. The first drug 
promising to fulfil these aims is lurasidone, which has a mixed pharmacology with antagonistic effects 
on dopamine D2 receptors and the 5-HT7 serotonergic receptor, and partial antagonistic effects on the 
5-HT1A serotonergic receptor185. In comparison to quetiapine, it has been shown to dose-dependently 
improve cognition measured with a composite measure as well as skills-based everyday functioning186. 
However, the long-term effects of this novel drug on cognition and everyday functioning, and 
particularly work and social functioning, have not yet been shown although it was only approved in 
the US in 2010 and in the EU in 2014. The last 10 years have seen a number of trials using drugs 
initially developed as antidementive drugs (ACHEIs) in schizophrenia. However, the initially positive 
reports could not be replicated in bigger samples or the effects  in memory, attention and processing 
speed were relatively small 187-190. Similarly, compounds aiming more specifically at nicotinic 
acetylcholine receptors and their subtypes showed relatively small effects in attention, working 
memory, planning and memory 191, 192. In parallel, research tried to modify the glutamatergic system in 
the hope of improving cognitive deficits in schizophrenia based on the hypothesis that a glutamatergic 
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dysfunction might underlie or at least contribute to the pathogenesis of schizophrenia (e.g. 193). 
However, amongst others, a couple of recent meta-analyses showed no significant effect of drugs that 
positively modify glutamatergic signalling or acting as agonists or co-activators on glutamatergic 
receptors188, 194-196. Similarly, the use of antidepressants aiming at manipulating the serotonergic 
system to improve cognition in schizophrenia was not successful in improving cognition, but did 
improve depressive symptoms (e.g. 197). Similar negative results were reported on other 
pharmacological mechanisms such as a H3 histamine receptor antagonist198, monoamineoxidase B-
inhibitor rasagiline199. One study in 71 patients showed improvements using the estrogen receptor 
modulator raloxifene in measures of memory in a placebo-controlled cross-over study200 which, 
however, remains to be replicated (see no significant effect in a recent study in 42 women201). One 
other review collated support for a combined treatment with galantamine and memantine, although 
this suggestion has yet to be conclusively tested202. Modafinil showed in a meta-analysis of 8 
randomized-controlled studies including 372 patients a small improvement in negative symptoms 
without worsening positive symptoms, but also without strong difference from placebo in direct tests 
of cognition203. One study combined cognitive training in schizophrenia patients with modafinil 
compared to placebo, but without an additional effect of modafinil204. Using modafinil in patients with 
schizophrenia who are high functioning or early in the course may well yield beneficial effects205-207. 
However, to date, most of the studies were conducted using chronically ill patients with relatively 
severe cognitive deficits. There are reasons to believe that with earlier treatment the development of 
cognitive impairments can be stopped or even reversed which might be easier to achieve than to repair 
damage that has already occurred208. And in addition, the lack of consistent results could be due to the 
neurobiological heterogeneity of schizophrenia as diagnostic category, meaning that with 
neurobiological criteria for subcategories treatment responders to specific and different cognitive 
treatments might be identified.  
In affective disorders, including particularly major depressive disorder (MDD) and bipolar disorder, 
there has been a strong move to finding mechanisms that can help alleviate the cognitive symptoms155 
that frequently remain even after the main affective symptoms are remitted151, 209 and which strongly 
impact on functional outcome (review in 210). A recent review211 summarised 26 studies focusing on 
the treatment of cognition in depression. In this review, the NMDA-receptor antagonist memantine did 
not show a cognition enhancing effect. Two other drugs typically used in the treatment of cognitive 
deficits in dementia, galantamine and donepezil, did not suggest a clear benefit for cognitive 
impairments in depressed older patients (with the limitation that more studies are needed for these 
drugs). Vortioxetine, a serotonergic antidepressant with reuptake-inhibiting and specific 5HT receptor 
activity, has received approval from the European Medicines Agency (EMEA) supporting the 
beneficial effect on cognitive functions in depression based on a big multicenter study in 602 
patients212 and it is currently in the process of being assessed by the US Food and Drug Administration 
for the specific indication of improving certain aspects of cognitive function in adults with MDD213. 
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The review by Solé211 mentions two studies214, 215 with positive effects of vortioxetine on attention, 
executive function, processing speed and verbal learning and memory independent from the 
improvement in mood, which is supported by an additional study comparing vortioxetine to the 
serotonin-noradrenaline reuptake inhibitor duloxetine212 with vortioxetine showing superiority over 
duloxetine in terms of improving cognition. However, it is not yet clear if vortioxetine also improves 
cognitive function in the absence of depression. In preclinical studies, selective serotonin reuptake 
inhibitors (SSRI) reversed the negative effects of stress and other models of depression on memory, 
whereas the effects of SSRI on memory in normal animals are rather mixed (review: 216). Vortioxetine, 
however, had rather consistent beneficial effects on memory in stressed and normal animals216. In 
animal models of executive function, both serotonergic and noradrenergic mechanisms have shown to 
improve stress-induced impairments216. Yet another mechanism of improving cognition in depression 
is the application of erythropoietin, which in one study showed a potential beneficial effect on clinical 
outcome as well as verbal learning (RAVLT) in MDD217 and on reaction time in remitted bipolar 
disorder218. In parallel to the idea to use stimulants to improve cognition in healthy people and in 
schizophrenia, a couple of studies have investigated if stimulants alone or as add on to antidepressants 
can improve clinical and cognitive outcome: In one study in elderly depressed patients the authors 
used citalopram, methylphenidate or the combination of both drugs in a placebo-controlled double 
blind design in nearly 150 patients219. The patients receiving the combination treatment showed a trend 
towards a faster and more pronounced clinical improvement compared to the other two treatment 
arms, but no clear difference between the treatments regarding cognitive improvement. A similar study 
used lisdexamfetamine (prodrug, converted into dextroamphetamine upon ingestion) as add on to 
SSRI treatment in partially remitted patients with self-reported executive dysfunction (placebo-
controlled) resulting in a stronger improvement in executive function, although reaching significance 
only in the self-report measure220. Except for the application as an add-on to improve antidepressant 
effects as summarized in a recent meta-analysis221, there are no studies clearly addressing a potential 
cognition enhancing effect of modafinil in depression. Ketamine is a NMDA receptor antagonist, 
whose rapid antidepressant effect was discovered in 2000222 and which has come more into the focus 
of research and clinical application in the last 5 years. Being originally an anaesthetic, it has been 
investigated regarding safety showing no negative neurocognitive effects in a number of studies211, 
and regarding potential neuroprotective effects during electroconvulsive therapy (ECT), but the few 
available studies have not resulted in a clear picture yet211. Based on the stress and inflammation 
hypothesis of depression one review summarizes a number of potential targets to improve cognition in 
depression223, but most of the compounds have not been tested yet in this respect. Goss, Kaser et al.221 
recommended modafinil as an add-on to antidepressant medication in depression. Similarly, a recent 
review on the effects of modafinil and other stimulants in unipolar and bipolar depression 
recommended modafinil as augmentation for depressive symptoms224. 
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In the field of addiction, the use of modafinil and stimulants has until now been mainly investigated 
for the treatment of the primary symptoms, i.e. addiction, craving, rather than for cognitive effects225. 
Attention-deficit-hyperactivity (ADHD) disorder is a paradigmatic disorder where stimulants 
(amphetamines), have long been used and are established treatments for the primary symptoms as well 
as for cognitive symptoms226, 227 – cognitive and primary symptoms are very closely linked in ADHD. 
Problems in sustained attention are core cognitive deficits, which can be improved by methylphenidate 
in both ADHD patients and healthy volunteers228, 229. In adult ADHD patients, stimulants have been 
shown to improve sustained attention, inhibition and verbal learning227. In 2014 and 2015, the most 
prominent research investigated an ongoing discussion about effects of stimulant treatment on general 
development, particularly reduced height and/or weight. Some studies resulted in small effects of 
stimulant treatment on the development of height and/or weight230, 231 in children, but some studies 
also found no effect232, review233. Considering that ADHD itself seems to be associated with increased 
body weight234, it could mean that the medication may normalize body development in ADHD. 
However, there is insufficient evidence to determine this as yet. 
A few studies investigated the effect of cognitive enhancers in other neuropsychiatric disorders such as 
Fragile X-syndrome235 (beneficial effect of 1-year treatment with memantine on cued verbal memory 
recall, but not free recall), traumatic brain injury236 (beneficial effect of methylphenidate on fatigue 
and psychomotor speed), post-radiation impairments in cancer patients237 (24 week treatment with 
donepezil, improved in some cognitive domains, stronger effect in more impaired patients) and a 
meta-analysis of 10 (mostly small) studies using modafinil in neurological disorders (Parkinson’s 
disease, multiple sclerosis, traumatic brain injury) reported rather inconsistent effects (trend towards 
improved excessive daytime sleepiness, but no effect on depression), concluded that more research in 
this field is needed238. 
One field that is gaining more attention is the combination of cognitive enhancers with psychotherapy, 
for instance in anxiety disorders. Particularly D-cycloserine (modulating (enhancing) the NMDA 
glutamate receptor) has been investigated with overall more positive than negative studies, but also 
other drugs are showing some positive effects (recent reviews: 239-243). Another approach is the 
combination of pharmacological cognitive enhancers with cognitive training. A recent study in 
patients with schizophrenia combined modafinil with cognitive training in a placebo-controlled design 
over 10 days204. There was a clear effect of cognitive training on measures of attention, working 
memory, learning and executive function, but no additional effect of modafinil compared to placebo. 
However, both these applications of cognitive enhancers (psychotherapy, cognitive training) are still in 
an experimental stage, requiring more systematic and randomized controlled studies. 
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In the preclinical field, studies are focusing on finding new targets with possible cognitive enhancing 
effects such as NMDA-receptors244, Phosphodiesterase inhibitors245, 246 (general review 247), D4 
dopaminergic receptor248, and serotonergic 5-HT 6 receptor249. 
 
Non-pharmacological interventions to enhance cognitive performance in 
neuropsychiatric disorders 
In the field of neuropsychiatric disorders, there are fewer studies investigating the effects of cognitive 
training and other interventions on cognition, although at least in mild to moderate neurocognitive 
disorders the benefits of, for instance, physical exercise combined with computerized cognitive 
training seem to be comparable or only moderately weaker than the improvements in healthy older 
adults250-252, and that even in patients with manifest, up to moderate AD a training of specific memory 
functions is possible and can be maintained over months253, 254, although the effects of specific 
cognitive training compared to multi-domain cognitive stimulation in a recent meta-analysis were 
weaker (moderate effect size for multi-domain cognitive stimulation)255.  
In the field of schizophrenia, there have been a couple of studies applying computerized as well as 
app-based and video-game based  trainings with mostly beneficial effects such as an improvement in 
cognitive flexibility as well as in everyday functioning after cognitive training using a specifically 
designed video game for 4 weeks. The recent study by Sahakian et al.21 used a neuroscientific 
approach to brain app development, combined with an integrative approach, including neuroscientists, 
a game developer and service users with schizophrenia. Game play with the Wizard memory app 
improved episodic memory and learning and patients’ social, occupational and psychological 
functioning. In addition, motivation remained high throughout the 8 hours of training over 4 weeks21. 
In general, the evidence is quite strong that cognitive training (also known as cognitive remediation) 
can improve cognition and everyday outcome in schizophrenia256-258, resulting in neuroplastic changes 
in brain activation259, 260. A recent study showed improvements even in patients diagnosed with 
schizophrenia without clear insight into their cognitive deficits261. In addition, research has recognized 
the importance of cognitive training particularly in patients early in the course of schizophrenia, after a 
first psychotic episode, to maintain and strengthen the patients’ resources already early in the course 
and to enable a rapid re-integration into social and work environments262-264, with some studies 
successfully targeting also social cognitive functions such as theory of mind directly265, whereas a 
recent review showed transfer effects of cognitive training onto social functions266. However, despite 
this rather strong overall body of evidence, only few treatment guidelines include neurocognitive 
training into their recommendations267, whereas the American Psychiatric Association, for instance, 
considers cognitive remediation therapy as ‘experimental and cannot yet be recommended as part of 
routine practice’ (although the last guideline is from 2004)268. However, one study in a group of 
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patients with mixed mental disorders showed that in patients who had failed in a trial of supported 
employment a specific cognitive training could increase their chance of employment to 60%269. 
In other neuropsychiatric disorders, there are fewer studies investigating the effects of cognitive 
training (e.g. in PTSD270, stress-related exhaustion271, etc.) whereas in mood and anxiety disorders, for 
instance, training modules still have to be developed272. 
RTMS as non-invasive stimulation method in depression has proven efficacious to improve clinical 
symptoms273, 274. In contrast, in studies investigating the effect of rTMS on cognition in depression the 
findings are more mixed (meta-analysis 275, newer study 276), with executive functions, memory and 
attention each bei g improved in two or more studies. One study suggested a baseline effect, with 
patients with higher executive function performance at baseline benefitting more276 than patients with 
lower baseline performance. 
Summary and conclusion 
Overall, maintaining, restoring and improving cognitive performance is of increasing relevance with 
respect to work and economic environments as well as general quality of life and health.  
From a neuroethical perspective, it is important to consider both the positive but also the negative 
forces, for example excessive stress or indirect coercion, on healthy individuals to enhance themselves 
at school, university or work277.  
In people suffering from neuropsychiatric disorders, the evidence for potential pharmacological 
interventions for improving cognition is growing, but fewer studies have investigated non-
pharmacological interventions. However, the potential gains due to interventions might even be larger 
than in healthy volunteers. It may be that combining pharmacological and non-pharmacological means 
of enhancement might produce greater benefits in terms of cognition and wellbeing for those with 
neuropsychiatric disorders. 
Viewing the increasing lifestyle use of cognitive enhancing drugs from a policy perspective, there is 
an urgency for a public-private partnership between the government and the pharmaceutical industry 
to evaluate the long-term safety and efficacy of drugs such as modafinil in healthy people. These types 
of study could eliminate the potential harms of the dangerous practice of internet purchasing of 
prescription only cognitive enhancing drugs, with its potential harms. 
As a society, we need to consider how to improve brain health and wellbeing to ensure a sustainable 
economy and a flourishing society for all. 
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Legend for tables: 
Table 1: Pharmacological cognitive enhancers discussed here 
Abbreviations: AChEI Acetylcholineesterase inhibitors, AD Alzheimer’s Dementia, ADHD attention 
deficit hyperactivity disorder, BD bipolar disorder, DLB dementia with Lewy bodies, MDD major 
depression, n-AChR nicotinic Acetylcholine Receptor, PD Parkinson Disease, MS multiple sclerosis, 
TBI traumatic brain injury, SSRI Selective Serotonine Reuptake Inhibitors, SZ Schizophrenia, PUFA 
poly-unsaturated fatty acids.  
 
 
Table 2: Non-pharmacological cognitive enhancement interventions discussed here 
Abbreviations: MCI mild cognitive impairment, AD Alzheimer’s Dementia, ADHD attention deficit 
hyperactivity disorder, SZ schizophrenia, MS multiple sclerosis, PD Parkinson’s Disease, TBI 
traumatic brain injury, PTSD post-traumatic stress disorder, CFS/ME chronic fatigue 
syndrome/myalgic encephalitis, HD Huntington’s Disease, TMS transcranial magnetic resonance 
stimulation, tDCS transcranial direct current stimulation, tACS transcranial alternating current 
stimulation, tRNS transcranial random noise stimulation, EEG electroencephalography, fMRI 
functional magnetic resonance imaging 
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Table 1: Pharmacological cognitive enhancers discussed here 
 
Abbreviations: AChEI Acetylcholineesterase inhibitors, AD Alzheimer’s Dementia, ADHD attention 
deficit hyperactivity disorder, BD bipolar disorder, DLB dementia with Lewy bodies, MDD major 
depression, n-AChR nicotinic Acetylcholine Receptor, PD Parkinson Disease, MS multiple sclerosis, 
TBI traumatic brain injury, SSRI Selective Serotonine Reuptake Inhibitors, SZ Schizophrenia, PUFA 
poly-unsaturated fatty acids.  
 
Substance
• Amphetamines 
• (Dex)Amphetamine
• Methylphenidate 
• Lisdexamfetamine
• AChEI 
• Donepezil
• Rivastigmine 
• Galantami e 
• Benzoate
• Clozapine
• Erythropoetin (EPO)
• H3 receptor 
antagonist
• Ketamine 
• Levodopa 
• Lurasidone 
• Memantine
• Modafinil 
• n-AChR agonists 
• Raloxifene
• Rapid acting insulin
• Rasagiline
• Resveratrol
• SSRI
• Tolcapone 
• Vortioxetine 
• PUFA
Cognitive domain/ 
function
• Attention
• spatial
• selective
• sustained 
• Executive function:
• mental addition
• fluid intelligence
• cognitive control
• cognitive flexibility
• working memory
• inhibition
• planning 
• decision making
• logical reasoning
• problem solving
• Memory 
• short term
• long term
• implicit
• spatial
• visual
• verbal
• Gait 
• Processing speed,  
reaction time
• Salience/distraction
• Speed, fatigue
• Creativity
• Self monitoring
• Emotion processing
• Multi-domain tasks
Condition
• Healthy adults 
• Healthy adults with 
PUFA deficiency
• AD
• ADHD
• Addiction
• BD
• DLB
• Fragile X syndrome
• MDD 
• MS
• PD
• Post-radiation 
impairment
• SZ
• TBI
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Table 2: Non-pharmacological cognitive enhancement interventions discussed here 
 
Abbreviations: MCI mild cognitive impairment, AD Alzheimer’s Dementia, ADHD attention deficit 
hyperactivity disorder, SZ schizophrenia, MS multiple sclerosis, PD Parkinson’s Disease, TBI 
traumatic brain injury, PTSD post-traumatic stress disorder, CFS/ME chronic fatigue 
syndrome/myalgic encephalitis, HD Huntington’s Disease, TMS transcranial magnetic resonance 
stimulation, tDCS transcranial direct current stimulation, tACS transcranial alternating current 
stimulation, tRNS transcranial random noise stimulation, EEG electroencephalography, fMRI 
functional magnetic resonance imaging 
 
Intervention
•cognitive training
•methods:
•reading
•group
•computer-based
•app-based
•game-based
•aim/domain
•specific
•gist training
•general
•aerobic exercise
•combination cognitive 
training + aerobic exercise
•Meditation/relaxation
•social engagement
•sleep hygiene
•family-based interventions
•non-specific cognitive 
(affective) engagement
•Electrical/electro-
magnetical methods
•TMS
•tDCS
•tACS
•tRNS
•neurofeedback
•EEG
•fMRI
•biofeedback
Cognitive domain/ function
•motor learning
•sensory discrimination
•executive function
•switching/flexibity
•interference
•working memory
•reasoning
•planning
•inhibition
•memory
•verbal
•spatial
•attention
•sustained
•switching
•fluid intelligence
•spatial abilities
•car driving performance
Condition 
•Healthy
•older healthy people
•Children
•Intellectual disabilities
•AD
•ADHD
•Addiction
•anxiety disorders
•cancer
•CFS/ME
•combat-related cognitive 
symptoms
•HD
•Hearing loss
•MCI
•MDD
•MS
•PD
•PTSD
•stress-related exhaustion
•stroke
•SZ
•TBI
•Tinnitus
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